ZYDUSWELL

- Disclosure under SEBI (PIT) Regulations, 2015, regarding the transmission of 27,250 equity shares from Late Jasodaben Babubhai Patel to Mr. Prashant Babubhai Patel, both members of the Promoter Group. - Date of intimation: August 21, 2026.

- Zydus Wellness Products Limited (ZWPL), a wholly-owned material subsidiary, received a 'CARE AA+; Stable' credit rating for its ₹12.00 crore long-term bank facilities from CARE Ratings Limited. - The Stable outlook reflects the Zydus Wellness Group's established market position and strong operational and financial support from its promoter group.

- Q1 FY27 Consolidated Net Sales grew 66.7% YoY to INR 14,299 million. - Q1 FY27 EBITDA grew 55.3% YoY to INR 2,417 million. - Reported Net Profit declined 7%; however, excluding amortization of acquired brands, net profit grew 26.5%. - International business delivered 24.8% like-to-like growth, while domestic business grew 4.6% led by Skin & Hair Care (34.5%) and Food & Nutrition (16%). - Seasonal brands declined 12% due to unseasonal summer, but management anticipates growth momentum to return in the coming quarters. - The company launched Complan Power Play milkshake and VieMax Diabetes Care, with a robust long-term innovation pipeline for the next 2-3 years. - Comfort Click business remains EPS accretive, and management expects continued margin improvement. - The effective tax rate for Q1 FY27 was ~27%, projected at 25% for FY27 (with a lower cash component initially), moving to a fully cash basis from next year.

- Zydus Wellness received an updated ESG rating from Crisil ESG Ratings & Analytics Ltd. - The company's ESG category has been upgraded from "Adequate" to "Strong." - The Crisil ESG rating increased from 59 (FY2025) to 66 (FY2026), with a fresh Crisil Core ESG rating of 70 for FY2026.

- Concall Schedule - Concall Date: Friday, August 14, 2026 - Conference Name: Equirus Annual India Conference 2026 - Hosted by: Equirus Securities - Type of Meeting: Group and one-on-one meeting

- The audio recording of the Investor Call on unaudited financial results for the quarter ended June 30, 2026, is available on the company's website. - The link to access the recording is provided.

- Shareholders at the 32nd AGM on August 4, 2026, approved the appointment of Mr. Apurva S. Diwanji as an Independent Director for a term of 5 years, effective May 18, 2026 to May 17, 2031.

- The 32nd Annual General Meeting of Zydus Wellness Limited was held on August 4, 2026. - All six resolutions were passed with the requisite majority. - Key resolutions passed include adoption of financial statements for FY26, re-appointment of Dr. Sharvil P. Patel as Non-Executive Director, appointment of Mr. Apurva S. Diwanji as Independent Director, ratification of Cost Auditors' remuneration, and declaration of a dividend of ₹1.20 per equity share for FY26.

- Consolidated Revenue ₹1,429.9 Cr vs ₹857.7 Cr (▲66.7% YoY) - EBITDA ₹241.7 Cr vs ₹155.6 Cr (▲55.3% YoY) - PAT ₹118.9 Cr - EBITDA Margin 16.9% vs 18.1% (▼120bps)

- Consolidated Revenue ₹14,370Mn vs ₹8,609Mn (▲67% YoY) - EBITDA ₹2,455Mn vs ₹1,586Mn (▲55% YoY) - PAT ₹1,189Mn vs ₹1,279Mn (▼7% YoY) - EBITDA Margin 17.1% vs 18.4% (▼130bps)